Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial
James Metz, MD
University of Pennsylvania Cancer
Last Modified: May 12, 2001
Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group
The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens, including a regimen without Cisplatin based therapy.
Materials and Methods:
This study included patients with stage IIIb and IV NSCLC.
Most patients were has ECOG performance status 0 or 1.
Patients were randomized to receive CG (n=166) vs CGV (n=176) vs GV/IV (n=175)
anemia and nausea/vomiting were significantly increased in the CGV regimen
The median survival, 1 year survival, and time to progression were not significantly different between the arms
The response rate, time to progression, and survival were the same for CG as the addition of a 3rd agent
The hematologic toxicity was increased in the Cisplatin containing arms
There was no survival differences between the regimens
The addition of a third agent to a Cisplatin containing regimen was not shown to increase the benefits for patients
The experimental arms in this study were not superior to the control are of CG
Aug 10, 2011 - Despite more toxic effects, doublet chemotherapy with carboplatin and weekly paclitaxel is associated with significantly higher survival benefits than monotheraphy with either vinorelbine or gemcitabine in elderly patients with advanced non-small-cell lung cancer, according to a study published online Aug. 9 in The Lancet.